Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-blind Trial to Compare the Efficacy of Rosuvastatin 5 and 10 mg to Atorvastatin 10 mg in the Treatment of High Risk Patients With Hypercholesterolemia Followed by an Open Label Treatment Period With Rosuvastatin Up-titrated to the Maximum Dose of 20 mg for Those Patients Who do Not Achieve Goal

NCT00683618 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00683618
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00683618 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-blind Trial to Compare the Efficacy of Rosuvastatin 5 and 10 mg to Atorvastatin 10 mg in the Treatment of High Risk Patients With Hypercholesterolemia Followed by an Open Label Treatment Period With Rosuvastatin Up-titrated to the Maximum Dose of 20 mg for Those Patients Who do Not Achieve Goal
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2008
Completion date
July 31, 2009
Enrollment
934 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hypercholesterolemia